



CODE/NAME & ADDRESS: C000138383

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

ACCESSION NO : 0080XC008157

PATIENT ID : SATYM15108180

CLIENT PATIENT ID:

AGE/SEX

RECEIVED : 23/03/2024 08:12:20 REPORTED : 23/03/2024 16:05:58

:42 Years

Test Report Status Final Results Biological Reference Interval Units

н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP A	BOVE 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	14.3	13.0 - 17.0	g/dL
METHOD: CYANMETHEMOGLOBIN METHOD			
RED BLOOD CELL (RBC) COUNT	4.97	4.5 - 5.5	mil/μL
METHOD : ELECTRICAL IMPEDANCE WHITE BLOOD CELL (WBC) COUNT	6.39	4.0 - 10.0	thou/µL
METHOD : ELECTRICAL IMPEDANCE	0.39	4.0 - 10.0	ι Ιου, με
PLATELET COUNT	256	150 - 410	thou/µL
METHOD: ELECTRICAL IMPEDANCE			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	45.6	40 - 50	%
METHOD : ELECTRICAL IMPEDANCE			
MEAN CORPUSCULAR VOLUME (MCV)	91.7	83 - 101	fL
METHOD : CALCULATED PARAMETER	20.0	27.0 22.0	
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	28.9	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN	31.5	31.5 - 34.5	g/dL
CONCENTRATION (MCHC)	31.3	31.3 34.3	3/ 4-
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	15.5 High	11.6 - 14.0	%
METHOD: CALCULATED PARAMETER MENTZER INDEX	18.5		
	11.2 High	6.8 - 10.9	fL
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	II.Z RIGII	6.8 - 10.9	IL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	54	40 - 80	%
METHOD: LIGHT ABSORBANCE OF CYTOCHEMICAL STAINED CELL		20 40	%
LYMPHOCYTES METHOD: LIGHT ABSORBANCE OF CYTOCHEMICAL STAINED CELL:	34 SIMPEDANCE	20 - 40	70
MONOCYTES	5 IMPEDANCE	2 - 10	%
11011001120	9	2 10	, 5

Deraraht.

Chandni Garg

DR.CHANDNI GARG
CONSULTANT PATHOLOGIST

Page 1 Of 19







View Details

View Report



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







CODE/NAME & ADDRESS: C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

: SATYM15108180

ACCESSION NO: 0080XC008157 AGE/SEX :42 Years

DRAWN

RECEIVED: 23/03/2024 08:12:20 REPORTED :23/03/2024 16:05:58

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

CLIENT PATIENT ID:

PATIENT ID

ABHA NO

METHOD: LIGHT ABSORBANCE OF CYTOCHEMICAL STAINED CELLS	IMPEDANCE		
EOSINOPHILS	7 High	1 - 6	%
BASOPHILS	0	0 - 2	%
METHOD: LIGHT ABSORBANCE OF CYTOCHEMICAL STAINED CELLS	IMPEDANCE		
ABSOLUTE NEUTROPHIL COUNT	3.45	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	2.17	1 - 3	thou/µL
ABSOLUTE MONOCYTE COUNT	0.32	0.20 - 1.00	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.45	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.6		

METHOD: CALCULATED PARAMETER

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

was considered the state of beta transferred that.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR =

This ratio element is a calculated parameter and out of NABL scope.

Deraralit

Dr. Pranjali Vasisht LAB HEAD

Chandri Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST





Page 2 Of 19



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







mm at 1 hr

REF. DOCTOR: SELF PATIENT NAME: SATYAM NIROLA

CODE/NAME & ADDRESS: C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0080XC008157

PATIENT ID

: SATYM15108180 CLIENT PATIENT ID:

ABHA NO

DRAWN

AGE/SEX

RECEIVED: 23/03/2024 08:12:20

:42 Years

REPORTED :23/03/2024 16:05:58

Test Report Status Biological Reference Interval Final Results Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R 04 0 - 14

METHOD: MODIFIED WESTERGREN

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

Non-diabetic Adult < 5.7 HBA1C 5.4 %

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0

(ADA Guideline 2021)

ESTIMATED AVERAGE GLUCOSE(EAG) 108.3 < 116.0 mg/dL

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE:

DR.CHANDNI GARG

Chardni Garg

(Desaraht

Dr.Pranjali Vasisht

Page 3 Of 19

CONSULTANT PATHOLOGIST

LAB HEAD







Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







REF. DOCTOR: SELF PATIENT NAME: SATYAM NIROLA

CODE/NAME & ADDRESS: C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

: SATYM15108180

ACCESSION NO: 0080XC008157 AGE/SEX :42 Years

DRAWN

RECEIVED: 23/03/2024 08:12:20 REPORTED :23/03/2024 16:05:58

ABHA NO

Test Report Status Results **Biological Reference Interval** <u>Final</u> Units

CLIENT PATIENT ID:

PATIENT ID

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients. 2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
- 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Chardni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST (Poraralit

Dr. Pranjali Vasisht LAB HEAD





Page 4 Of 19



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







Units

PATIENT NAME: SATYAM NIROLA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138383

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

Test Report Status

8800465156

ACCESSION NO : 0080XC008157

PATIENT ID : SATYM15108180

CLIENT PATIENT ID: ABHA NO : DD 4 14/11 .

AGE/SEX

Biological Reference Interval

RECEIVED : 23/03/2024 08:12:20 REPORTED : 23/03/2024 16:05:58

:42 Years

____i

IMMUNOHAEMATOLOGY

Results

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

<u>Final</u>

ABO GROUP TYPE B

METHOD : SLIDE AGGLUTINATION

RH TYPE POSITIVE

METHOD: SLIDE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Oparalit.

Dr.Pranjali Vasisht LAB HEAD Chardni Garg

DR.CHANDNI GARG
CONSULTANT PATHOLOGIST





Page 5 Of 19

View Details

View Report



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







PATIENT NAME: SATYAM NIROLA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138383

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO : 0080XC008157

PATIENT ID : SATYM15108180

CLIENT PATIENT ID: ABHA NO : AGE/SEX :42 Years

DRAWN :

RECEIVED: 23/03/2024 08:12:20 REPORTED: 23/03/2024 16:05:58

Test Report Status <u>Final</u> Results Biological Reference Interval Units

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)

98

74 - 106

mg/dL

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

101

Non-Diabetes

mg/dL

70 - 140

METHOD: HEXOKINASE

METHOD: HEXOKINASE

LIPID PROFILE WITH CALCULATED LDL, SERUM

CHOLESTEROL, TOTAL 182

< 200 Desirable

mg/dL

200 - 239 Borderline High >/= 240 High

METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES

160 High

< 150 Normal

mg/dL

150 - 199 Borderline High 200 - 499 High

>/= 500 Very High

METHOD: ENZYMATIC ASSAY

HDL CHOLESTEROL

37 Low

< 40 Low

mg/dL

mg/dL

>/=60 High

 ${\tt METHOD:DIRECT\:MEASURE-PEG}$

CHOLESTEROL LDL

113 High

< 100 Optimal

100 - 129

Near or above optimal

130 - 159 Borderline High

160 - 189 High >/= 190 Very High

 ${\tt METHOD: CHOLESTEROL\ OXIDASE,\ ESTERASE, PEROXIDASE}$

Chardni Garg

Chronalit

Page 6 Of 19

DR.CHANDNI GARG
CONSULTANT PATHOLOGIST

Dr.Pranjali Vasisht LAB HEAD





View Details

View Report



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







CODE/NAME & ADDRESS : C000138383 ACCESSION NO : **0080XC008157**ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SATYM15108180

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

REIT DOCTOR : SEE

ACCESSION NO: **0080XC008157** AGE/SEX: 42 Years Male

DRAWN :

RECEIVED : 23/03/2024 08:12:20 REPORTED : 23/03/2024 16:05:58

 I I	1
I I	1
I I	1
l l	1
 ı	1
 ı	1
 ı	1

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
NON HDL CHOLESTEROL	37	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220
METHOD: CALCULATED PARAMETER		, ,
VERY LOW DENSITY LIPOPROTEIN	32.0	Desirable value : mg/dL 10 - 35
METHOD: CALCULATED PARAMETER		
CHOL/HDL RATIO	4.9 High	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk
METHOD: CALCULATED PARAMETER		-
LDL/HDL RATIO	3.1 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk
METHOD: CALCULATED PARAMETER		

CLIENT PATIENT ID:

ABHA NO

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 1	najor risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk		betes with 1 major risk factor or no evidence of end organ	
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors		
1. Age $>$ or $=$ 45 year	1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of premature ASCVD 4. High blood pressure			
5. Low HDL			

Chardni Garg

DR.CHANDNI GARG

Coraculit

Dr.Pranjali Vasisht LAB HEAD Page 7 Of 19







View Report



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel: 9111591115, Fax:

IEI: 9111591115, Fax: CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS : C000138383 ACCESSION NO : **0080XC008157** AGE/SEX : 42 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SATYM15108180 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/03/2024 08:12:20

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

tewer treatment goals and statin initiation thresholds based on the risk categories proposed by 12x1 in 2020.				
Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <or 60)<="" =="" td=""><td>>OR = 50</td><td>>OR = 80</td></or>	>OR = 50	>OR = 80
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.56	UPTO 1.2	mg/dL
METHOD: DIAZONIUM ION, BLANKED (ROCHE)			
BILIRUBIN, DIRECT	0.17	0.00 - 0.30	mg/dL
METHOD: DIAZOTIZATION			
BILIRUBIN, INDIRECT	0.39	0.00 - 0.60	mg/dL
METHOD: CALCULATED PARAMETER			
TOTAL PROTEIN	7.2	6.6 - 8.7	g/dL
METHOD : BIURET			
ALBUMIN	4.7	3.97 - 4.94	g/dL
METHOD: BROMOCRESOL GREEN			
GLOBULIN	2.5	2.0 - 4.0	g/dL
		Neonates -	
		Pre Mature:	
		0.29 - 1.04	
METHOD: CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.9	1.0 - 2.0	RATIO
METHOD: CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	30	0 - 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	51 High	0 - 41	U/L
METHOD: UV WITHOUT PYRIDOXAL-5 PHOSPHATE			
ALKALINE PHOSPHATASE	121	40 - 129	U/L
METHOD: PNPP - AMP BUFFER			
GAMMA GLUTAMYL TRANSFERASE (GGT)	25	8 - 61	U/L
METHOD : GAMMA GLUTAMYLCARBOXY 4NITROANILIDE			
LACTATE DEHYDROGENASE	169	135 - 225	U/L
METHOD : LACTATE -PYRUVATE			

Chardni Garg

Coracult

Dr.Pranjali Vasisht LAB HEAD



Page 8 Of 19






DR.CHANDNI GARG

Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956







PATIENT NAME: SATYAM NIROLA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0080XC008157

PATIENT ID : SATYM15108180

CLIENT PATIENT ID: ABHA NO

AGE/SEX :42 Years

RECEIVED: 23/03/2024 08:12:20 REPORTED :23/03/2024 16:05:58

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 10 6 - 20mg/dL

METHOD: UREASE - UV

CREATININE, SERUM

CREATININE 1.26 High 0.70 - 1.20mg/dL

METHOD: ALKALINE PICRATE-KINETIC

BUN/CREAT RATIO

7.94 5.00 - 15.00 BUN/CREAT RATIO

METHOD: CALCULATED PARAMETER

URIC ACID, SERUM

URIC ACID 7.9 High 3.4 - 7.0mg/dL

METHOD: URICASE, COLORIMETRIC

TOTAL PROTEIN, SERUM

TOTAL PROTEIN 7.2 6.6 - 8.7g/dL

METHOD : BIURET

ALBUMIN, SERUM

4.7 3.97 - 4.94g/dL ALBUMIN

METHOD: BROMOCRESOL GREEN

Coraculit

DR.CHANDNI GARG CONSULTANT PATHOLOGIST Dr.Pranjali Vasisht LAB HEAD



Page 9 Of 19





Chardni garg

Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS: C000138383

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

ACCESSION NO: 0080XC008157

PATIENT ID : SATYM15108180

CLIENT PATIENT ID: ABHA NO : AGE/SEX : DRAWN :

RECEIVED : 23/03/2024 08:12:20 REPORTED :23/03/2024 16:05:58

:42 Years

Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
CLODULTN			
GLOBULIN			
GLOBULIN	2.5	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD: CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM METHOD: ISE INDIRECT	143	136 - 145	mmol/L
POTASSIUM, SERUM METHOD: ISE INDIRECT	4.48	3.5 - 5.1	mmol/L
CHLORIDE, SERUM METHOD: ISE INDIRECT	105	98 - 107	mmol/L

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessives weating, severe vomiting or diarrhea), diabetes mellitus, diabetes in sipidus, hyperaldosteronism, in adequate water intake. Drugs: steroids, licorice, or al contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.

Chardni Garg

DR.CHANDNI GARG
CONSULTANT PATHOLOGIST

Coraculit

Dr.Pranjali Vasisht LAB HEAD





Page 10 Of 19

View Details

View Report



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







REF. DOCTOR: SELF PATIENT NAME: SATYAM NIROLA

CODE/NAME & ADDRESS: C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO : 0080XC008157

PATIENT ID : SATYM15108180

CLIENT PATIENT ID: ABHA NO

DRAWN

AGE/SEX

RECEIVED: 23/03/2024 08:12:20

:42 Years

REPORTED: 23/03/2024 16:05:58

Test Report Status Results Biological Reference Interval **Final** Units

Interferences: Severe linemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.

Interferences: Hemolysis of sample. delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.

Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides. Decreased in:Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c

LIVER FUNCTION PROFILE, SERUM
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive

liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. **Total Protein** also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc
BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.
CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels:-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Chardni Garg

(Desaraht

Page 11 Of 19

DR.CHANDNI GARG CONSULTANT PATHOLOGIST Dr. Pranjali Vasisht LAB HEAD







Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS: C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0080XC008157

PATIENT ID : SATYM15108180

CLIENT PATIENT ID: ABHA NO

AGE/SEX

RECEIVED: 23/03/2024 08:12:20

:42 Years

REPORTED :23/03/2024 16:05:58

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Chardni garg

DR.CHANDNI GARG **CONSULTANT PATHOLOGIST** Coraculit

Dr.Pranjali Vasisht LAB HEAD





Page 12 Of 19



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







PATIENT NAME: SATYAM NIROLA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0080XC008157

PATIENT ID : SATYM15108180

CLIENT PATIENT ID: ABHA NO

AGE/SEX :42 Years

RECEIVED: 23/03/2024 08:12:20 REPORTED :23/03/2024 16:05:58

Biological Reference Interval Units Test Report Status Results **Final**

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

PH 6.0 4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD 1.003 - 1.035 SPECIFIC GRAVITY 1.020

METHOD: REFLECTANCE SPECTROPHOTOMETRY (PKA CHANGE OF PRETREATED POLY ELECTROLYTES)

NOT DETECTED **PROTEIN** NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY (PROTEIN-ERROR-OF-INDICATORS PRINCIPLE) NOT DETECTED NOT DETECTED GLUCOSE

METHOD: REFLECTANCE SPECTROPHOTOMETRY(GLUCOSE OXIDAE/PEROXIDASE METHOD) NOT DETECTED KFTONES NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY (SODIUM NITROPRUSSIDE REACTION)

NOT DETECTED BLOOD NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY (PEROXIDASE METHOD)

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION)

UROBILINOGEN **NORMAL NORMAL**

METHOD: REFLECTANCE SPECTROPHOTOMETRY - EHRLICH REACTION

NITRITE NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

/HPF **NOT DETECTED** RED BLOOD CELLS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 1-2 0 - 5/HPF

METHOD: MICROSCOPIC EXAMINATION

0-1 0-5 /HPF EPITHELIAL CELLS

METHOD: MICROSCOPIC EXAMINATION

Chardni Garg DR.CHANDNI GARG

Dr.Pranjali Vasisht LAB HEAD

Deraralit



Page 13 Of 19





Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS : C000138383 ACCESSION NO: 0080XC008157 AGE/SEX :42 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SATYM15108180

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 23/03/2024 08:12:20

DELHI REPORTED :23/03/2024 16:05:58 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status Final Results Biological Reference Interval Units

NOT DETECTED **CASTS** NOT DETECTED **CRYSTALS**

METHOD: MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

YEAST NOT DETECTED NOT DETECTED

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis

Chardni garg

DR.CHANDNI GARG

Coracalit

Dr.Pranjali Vasisht LAB HEAD

Page 14 Of 19









Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS: C000138383

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0080XC008157

PATIENT ID : SATYM15108180

CLIENT PATIENT ID: ABHA NO : AGE/SEX :42 Y

:42 Years Male

DRAWN :

RECEIVED : 23/03/2024 08:12:20 REPORTED : 23/03/2024 16:05:58

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Bacteria Urinary infectionwhen present in significant numbers & with pus cells.

Trichomonas vaginalis Vaginitis, cervicitis or salpingitis

Chardni garg

DR.CHANDNI GARG
CONSULTANT PATHOLOGIST

Obrasalit.

Dr.Pranjali Vasisht LAB HEAD





Page 15 Of 19

View Details





Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







RECEIVED: 23/03/2024 08:12:20

PATIENT NAME: SATYAM NIROLA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138383 :42 Years ACCESSION NO: 0080XC008157 AGE/SEX Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SATYM15108180 DRAWN

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: DELHI

ABHA NO REPORTED :23/03/2024 16:05:58 **NEW DELHI 110030** 8800465156

Test Report Status Results Biological Reference Interval Units <u>Final</u>

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, STOOL

COLOUR BROWN

CONSISTENCY SEMI FORMED

MUCUS NOT DETECTED NOT DETECTED

VISIBLE BLOOD **ABSENT ABSENT**

ADULT PARASITE NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

CHEMICAL EXAMINATION, STOOL

STOOL PH 7.0

MICROSCOPIC EXAMINATION, STOOL

/hpf **PUS CELLS** 1-2 **RED BLOOD CELLS NOT DETECTED** /HPF

NOT DETECTED

CYSTS NOT DETECTED NOT DETECTED

OVA NOT DETECTED

LARVAE NOT DETECTED NOT DETECTED **TROPHOZOITES NOT DETECTED** NOT DETECTED

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis

Dr. Nidhi Garg Lab Consultant



Page 16 Of 19



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







CODE/NAME & ADDRESS: C000138383 ACCESSION NO: 0080XC008157 AGE/SEX :42 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

PATIENT ID F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

: SATYM15108180

CLIENT PATIENT ID: ABHA NO

RECEIVED: 23/03/2024 08:12:20

REPORTED :23/03/2024 16:05:58

Biological Reference Interval Test Report Status Results Units **Final**

Parasites	Infection of the digestive system. Stool examination for ova and parasite detects
Farasites	presence of parasitic infestation of gastrointestinal tract. Various forms of
	parasite that can be detected include cyst, trophozoite and larvae. One negative
	result does not rule out the possibility of parasitic infestation. Intermittent
	shedding of parasites warrants examinations of multiple specimens tested on
	consecutive days. Stool specimens for parasitic examination should be collected
	before initiation of antidiarrheal therapy or antiparasitic therapy. This test does
	not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia
	and Isospora species. Examination of Ova and Parasite has been carried out by
	direct and concentration techniques.
**	
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to
	bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up
•	in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
pН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

ADDITIONAL STOOL TESTS:

- Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) 2. from Irritable Bowel Syndrome (IBS).
- 3. Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- 4. Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr. Nidhi Garg Lab Consultant

Page 17 Of 19







Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







CODE/NAME & ADDRESS : C000138383 ACCESSION
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

..... 00007000157

ACCESSION NO: 0080XC008157 AGE/SEX: 42 Years Male

: SATYM15108180 DRAWN

RECEIVED : 23/03/2024 08:12:20 REPORTED :23/03/2024 16:05:58

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLIENT PATIENT ID:

ABHA NO

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

THYROID PANEL, SERUM

T3 117.10 80.00 - 200.00 ng/dL

METHOD : COMPETITIVE (ECLIA)

T4 6.01 5.10 - 14.10 μ g/dL

METHOD: COMPETITIVE (ECLIA)

TSH (ULTRASENSITIVE) 4.110 0.270 - 4.200 μ IU/mL METHOD: SANDWICH (ECLIA)

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Chardni Garg

Dr.Pranjali Vasisht LAB HEAD

Parallet

Page 18 Of 19

DR.CHANDNI GARG
CONSULTANT PATHOLOGIST





View Details

View Report



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India







PATIENT NAME: SATYAM NIROLA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138383

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO : 0080XC008157

PATIENT ID : SATYM15108180

CLIENT PATIENT ID: ABHA NO : AGE/SEX :

RECEIVED : 23/03/2024 08:12:20 REPORTED :23/03/2024 16:05:58

:42 Years

Test Report Status Final Results Biological Reference Interval Units

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Chardni Garg

Parault

Dr.Pranjali Vasisht LAB HEAD Page 19 Of 19

DR.CHANDNI GARG
CONSULTANT PATHOLOGIST





View Details

View Report



Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India

